Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 9/20 | 0.54 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378461 | 0.85 | KCNA5 (0.45) | KCNA5KCND3CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL1381075 | 0.82 | KCNA5 (0.42) | KCNA5KCND3CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL1381261 | 0.78 | CYP19A1 (0.49) | KCNA5CYP19A1CYP11B1 | |
| SCHEMBL1381350 | 0.78 | CYP19A1 (0.49) | KCNA5CYP19A1CYP11B1 | |
| SCHEMBL11629773 | 0.78 | SMN1; SMN2 (0.62) | KCNA5KCND3CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL6502308 | 0.74 | CYP19A1 (0.50) | KCNA5CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3887188 | 0.74 | CFTR (0.62) | KCNA5CYP19A1SLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL6000004 | 0.73 | CYP19A1 (0.49) | KCNA5CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3886807 | 0.72 | KCNA5 (0.56) | KCNA5KCND3CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL1243292 | 0.72 | POLB (0.54) | KCNA5CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | KCNN2, KCNJ2, KCNH2 | KCNA5 14/4885KCND3 41/4885CYP19A1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.